Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01210430
Other study ID # 2R01HL074873-06A2
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date July 2010
Est. completion date June 2015

Study information

Verified date June 2021
Source New York Medical College
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators study will determine how often blood flow regulation abnormalities and abnormalities of sympathetic regulation produced by nitric oxide, angiotensin-II, and oxidative stress occur in POTS and the mechanism(s) of POTS in individual patients. Specific causes for POTS may vary from patient to patient. Patients will be compared to healthy control subjects. There is a treatment arm with a medication (losartan) that reduces the binding of angiotensin and increases NO. If the investigators know the specific biochemical mechanism the investigators may be able to offer further specific treatments to specific patients.


Description:

Chronic orthostatic intolerance due to the postural tachycardia syndrome (POTS) severely impairs daily life in over a million Americans, mostly young women. POTS is defined by symptoms of orthostatic intolerance associated with excessive upright heart rate. While there is general agreement that abnormalities in vascular regulation and autonomic activity account for the tachycardia and symptoms of POTS, its pathophysiology is heterogeneous and only partially characterized. The key feature of POTS is symptoms which are most prominent when standing. However, in some, findings are present supine (lying down) but worsened standing. Symptoms of POTS include dizziness in all patients, exercise provoked symptoms and thus exercise intolerance, excessive fatigue, nausea and abdominal pain, headache, shortness of breath and deep breathing, weakness, shakiness and postural anxiety, pallor, and neurocognitive loss (difficulty thinking). These occur on a day-to-day basis. The symptoms overlap with the case definition of chronic fatigue syndrome (CFS) and POTS is often found in CFS in the young. Fainting is relatively uncommon during daily life. A major subset of POTS has increased peripheral resistance and low blood flow(LFP) related to increased angiotensin-II (Ang-II), and decreased nitric oxide (NO). NO deficits are reversed by Ang-II type-1 receptor (AT1R) blockade, ascorbic acid (AA) and tetrahydrobiopterin in skin suggesting the importance of oxidative stress. Preliminary data also suggest that the coupling of sympathetic nerve activity to blood vessel contraction is enhanced via ↑Ang-II and ↓NO. We hypothesize that this is due to activation of reactive oxygen species (ROS) including superoxide, which scavenges NO to generate peroxynitrite, and hydrogen peroxide. Combined measurements in the skin and the systemic circulation will be combined with local measurement of ROS production and sympathetic nerve activity will enable us to determine precisely how the autonomic nervous system is affected by the illness. Methods include cutaneous microdialysis to measure ROS, skin biopsy and blood tests to measure gene expression of nitric oxide synthase and Ang-II receptors, and peroneal microneurography to measure muscle sympathetic nerve activity (MSNA). Combined with ultrasonic femoral artery blood flow this will yield assessment of the interactions of nerves with the blood vessels that they control. If we discover specific biochemical mechanisms of POTS in patients, then we may be able to specifically treat the defect.


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date June 2015
Est. primary completion date June 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 29 Years
Eligibility Inclusion Criteria: - Cases will be between the ages of 14 and 29 years old referred for evaluation of orthostatic intolerance with 3 or more of the following symptoms for at least 3 months: - dizziness - nausea and vomiting - palpitations - fatigue - headache - exercise intolerance - blurred vision - abnormal sweating heat. - Cases will have the diagnosis of symptomatic postural tachycardia made during a screening tilt table test. - Cases will have normal physical examination, and normal electrocardiographic and echocardiographic evaluations. - Only those free from heart disease, and from systemic illness will be eligible to participate. - This excludes patients with illnesses and disease states known to be associated with endothelial cell dysfunction such as diabetes, renal disease, congestive heart failure, systemic hypertension, acute and chronic inflammatory diseases, neoplasm, immune mediated disease, trauma, morbid obesity and peripheral vascular disease. - At the time of testing all patients and control subjects must refrain from vasoactive drugs for two weeks. Please check with us about any medication that you are taking. Exclusion Criteria: - Criteria for initial exclusion will include a condition known to be associated with endothelial dysfunction - An active medical condition that may explain the diagnosis - A previous medical condition with undocumented resolution that may explain the diagnosis - Past or present major psychiatric disorder - Substance abuse within 2 years before onset of symptoms.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Losartan
Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
Ascorbic Acid (Vitamin C)
Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
Normal Saline
Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.

Locations

Country Name City State
United States New York Medical College/Bradhurst building Hawthorne New York

Sponsors (1)

Lead Sponsor Collaborator
New York Medical College

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Orthostatic tolerance measured by the heart rate and blood pressure response to upright tilt 2 months
Secondary Sympathetic activation and blood flow measured by sympathetic nerve recordings and Doppler blood flow in the leg 2 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03124355 - Vagal Stimulation in POTS Phase 1
Recruiting NCT04310644 - Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry
Completed NCT03253120 - Alterations of Attention in POTS Depending on Body Position and Hydration N/A
Completed NCT03919773 - IVIG (Gamunex-C) Treatment Study for POTS Subjects Phase 1/Phase 2
Active, not recruiting NCT01988883 - Modafinil and Cognitive Function in POTS Early Phase 1
Active, not recruiting NCT01000350 - Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS) N/A
Recruiting NCT00409435 - A Study of Pyridostigmine in Postural Tachycardia Syndrome Phase 2
Completed NCT00770484 - Effect of Exercise in OI N/A
Completed NCT00581022 - Objective Sleep Disturbances in Orthostatic Intolerance
Terminated NCT00748228 - Dopamine in Orthostatic Tolerance N/A
Active, not recruiting NCT05630040 - VNS for Long-COVID-19 N/A
Recruiting NCT04632134 - Long-term Effects of Transcutaneous Vagal Nerve Stimulation on Postural Orthostatic Tachycardia Syndrome (POTS) N/A
Completed NCT00685919 - Peripheral Dopamine in Postural Tachycardia Syndrome Phase 2/Phase 3
Completed NCT00061009 - Hypnosis in Autonomic Function N/A
Recruiting NCT05618054 - Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities? N/A
Completed NCT01366963 - Cognitive Dysfunction in Postural Tachycardia Syndrome N/A
Recruiting NCT05107635 - Inappropriate Sinus Tachycardia Registry
Terminated NCT02154009 - Clinical Autonomic Disorders: A Training Protocol
Completed NCT03602482 - Standing Cognition and Co-morbidities of POTS Evaluation N/A
Completed NCT02167412 - EEG Characteristics in Youth POTS and/or Syncope

External Links